The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Biofrontera Inc is $6.00, about 380% above its August 12 closing price of $1.25
The stock recently traded at 513 times the next 12-month earnings vs. a P/E of 48 three months ago
BFRI•
